{"disease": {"name": "Prostate cancer", "mondo_id": null, "ncit_id": null, "umls_id": null, "oncotree_code": "prad"}, "updated_at": "2026-09-18", "genome_builds": ["hg19"], "cohort_count": 3, "cohort_count_status": "observed", "cohort_count_unit": "cohorts", "evaluable_patients": null, "evaluable_patients_status": "unknown", "evaluable_patients_unit": "patients", "alteration_types": ["SNV", "small indel", "amplification", "deep deletion"], "genes": [{"gene": "AR", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 2, "tested": 494, "frequency": 0.4, "cohort_count": 3, "frequency_range": {"min": 0.4, "max": 4.74}, "major_variants": ["A597T (n=1)", "R608Q (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Curated target in the disease briefing.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 2/494 patients (0.4%).", "Without the 4 hypermutated patients: 2/490 (0.41%).", "Largest alteration is amplification: 5/489 (1.02%) in the reference cohort's copy-number profile.", "Observed in 3 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 2, "tested": 494, "frequency": 0.4, "frequency_excl_hypermutated": 0.41, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 48, "tested": 1013, "frequency": 4.74, "frequency_excl_hypermutated": 4.42, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": 93, "tested": 2257, "frequency": 4.12, "frequency_excl_hypermutated": 4.08, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 3.4, "width": 1.0, "reference": 3.4, "scale_max": 30.0}, "headline_alteration": {"kind": "amplification", "altered": 5, "tested": 489, "frequency": 1.02, "is_mutation": false}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "FOLH1", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 0, "tested": 494, "frequency": 0.0, "cohort_count": 1, "frequency_range": {"min": 0.0, "max": 0.1}, "major_variants": [], "evidence_confidence": "moderate", "disease_relevance": "Curated target in the disease briefing.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 0/494 patients (0.0%).", "Without the 4 hypermutated patients: 0/490 (0.0%).", "Largest alteration is deep deletion: 2/489 (0.41%) in the reference cohort's copy-number profile.", "Observed in 1 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 0, "tested": 494, "frequency": 0.0, "frequency_excl_hypermutated": 0.0, "counting_unit": "patients", "status": "not_observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 1, "tested": 1013, "frequency": 0.1, "frequency_excl_hypermutated": 0.0, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": null, "tested": null, "frequency": null, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_assayed", "assayed": false, "assay_note": "Not on this cohort's gene panel.", "evaluable": false, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 1.37, "width": 1.0, "reference": 1.37, "scale_max": 30.0}, "headline_alteration": {"kind": "deep deletion", "altered": 2, "tested": 489, "frequency": 0.41, "is_mutation": false}, "altered_status": "not_observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "not_observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "CYP17A1", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 1, "tested": 494, "frequency": 0.2, "cohort_count": 2, "frequency_range": {"min": 0.2, "max": 0.2}, "major_variants": ["I104S (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Curated target in the disease briefing.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 1/494 patients (0.2%).", "Without the 4 hypermutated patients: 0/490 (0.0%).", "Largest alteration is deep deletion: 6/489 (1.23%) in the reference cohort's copy-number profile.", "Observed in 2 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 1, "tested": 494, "frequency": 0.2, "frequency_excl_hypermutated": 0.0, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 2, "tested": 1013, "frequency": 0.2, "frequency_excl_hypermutated": 0.1, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": null, "tested": null, "frequency": null, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_assayed", "assayed": false, "assay_note": "Not on this cohort's gene panel.", "evaluable": false, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 4.1, "width": 1.0, "reference": 4.1, "scale_max": 30.0}, "headline_alteration": {"kind": "deep deletion", "altered": 6, "tested": 489, "frequency": 1.23, "is_mutation": false}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "BRCA2", "alteration_types": ["SNV / small indel", "deep deletion", "amplification"], "altered": 8, "tested": 494, "frequency": 1.62, "cohort_count": 3, "frequency_range": {"min": 1.62, "max": 3.99}, "major_variants": ["N433Tfs*27 (n=1)", "N1435T (n=1)", "V726Sfs*25 (n=1)", "S3364Ifs*4 (n=1)", "D281H (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Curated target in the disease briefing.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 8/494 patients (1.62%).", "Without the 4 hypermutated patients: 7/490 (1.43%).", "Largest alteration is deep deletion: 17/489 (3.48%) in the reference cohort's copy-number profile.", "Observed in 3 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 8, "tested": 494, "frequency": 1.62, "frequency_excl_hypermutated": 1.43, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 29, "tested": 1013, "frequency": 2.86, "frequency_excl_hypermutated": 2.51, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": 90, "tested": 2257, "frequency": 3.99, "frequency_excl_hypermutated": 3.86, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 11.6, "width": 1.0, "reference": 11.6, "scale_max": 30.0}, "headline_alteration": {"kind": "deep deletion", "altered": 17, "tested": 489, "frequency": 3.48, "is_mutation": false}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "ATM", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 20, "tested": 494, "frequency": 4.05, "cohort_count": 3, "frequency_range": {"min": 3.75, "max": 4.25}, "major_variants": ["G2695S (n=1)", "G1672A (n=1)", "E2164K (n=1)", "L1936S (n=1)", "W484* (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Curated target in the disease briefing.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 20/494 patients (4.05%).", "Without the 4 hypermutated patients: 20/490 (4.08%).", "Observed in 3 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 20, "tested": 494, "frequency": 4.05, "frequency_excl_hypermutated": 4.08, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 38, "tested": 1013, "frequency": 3.75, "frequency_excl_hypermutated": 3.42, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": 96, "tested": 2257, "frequency": 4.25, "frequency_excl_hypermutated": 4.13, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 12.5, "width": 1.67, "reference": 13.5, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 20, "tested": 494, "frequency": 4.05, "is_mutation": true}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "PTEN", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 18, "tested": 494, "frequency": 3.64, "cohort_count": 3, "frequency_range": {"min": 3.64, "max": 7.98}, "major_variants": ["T319Ffs*5 (n=1)", "V119F (n=1)", "D326G (n=1)", "X70_splice (n=1)", "L220Qfs*3 (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Curated target in the disease briefing.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 18/494 patients (3.64%).", "Without the 4 hypermutated patients: 18/490 (3.67%).", "Largest alteration is deep deletion: 85/489 (17.38%) in the reference cohort's copy-number profile.", "Observed in 3 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 18, "tested": 494, "frequency": 3.64, "frequency_excl_hypermutated": 3.67, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 43, "tested": 1013, "frequency": 4.24, "frequency_excl_hypermutated": 4.02, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": 180, "tested": 2257, "frequency": 7.98, "frequency_excl_hypermutated": 7.86, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 57.93, "width": 1.0, "reference": 57.93, "scale_max": 30.0}, "headline_alteration": {"kind": "deep deletion", "altered": 85, "tested": 489, "frequency": 17.38, "is_mutation": false}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "TP53", "alteration_types": ["SNV / small indel", "deep deletion"], "altered": 57, "tested": 494, "frequency": 11.54, "cohort_count": 3, "frequency_range": {"min": 11.54, "max": 28.71}, "major_variants": ["R248Q (n=4)", "G245S (n=3)", "R175H (n=2)", "R282W (n=2)", "Y163H (n=2)"], "evidence_confidence": "moderate", "disease_relevance": "Curated target in the disease briefing.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 57/494 patients (11.54%).", "Without the 4 hypermutated patients: 55/490 (11.22%).", "Observed in 3 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 57, "tested": 494, "frequency": 11.54, "frequency_excl_hypermutated": 11.22, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 188, "tested": 1013, "frequency": 18.56, "frequency_excl_hypermutated": 18.09, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": 648, "tested": 2257, "frequency": 28.71, "frequency_excl_hypermutated": 28.63, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 38.47, "width": 57.23, "reference": 38.47, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 57, "tested": 494, "frequency": 11.54, "is_mutation": true}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "RB1", "alteration_types": ["SNV / small indel", "deep deletion"], "altered": 3, "tested": 494, "frequency": 0.61, "cohort_count": 3, "frequency_range": {"min": 0.61, "max": 3.23}, "major_variants": ["F226L (n=1)", "X405_splice (n=1)", "G617Rfs*36 (n=1)", "L337Ffs*4 (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Curated target in the disease briefing.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 3/494 patients (0.61%).", "Without the 4 hypermutated patients: 2/490 (0.41%).", "Largest alteration is deep deletion: 46/489 (9.41%) in the reference cohort's copy-number profile.", "Observed in 3 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 3, "tested": 494, "frequency": 0.61, "frequency_excl_hypermutated": 0.41, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 15, "tested": 1013, "frequency": 1.48, "frequency_excl_hypermutated": 1.01, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": 73, "tested": 2257, "frequency": 3.23, "frequency_excl_hypermutated": 3.11, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 31.37, "width": 1.0, "reference": 31.37, "scale_max": 30.0}, "headline_alteration": {"kind": "deep deletion", "altered": 46, "tested": 489, "frequency": 9.41, "is_mutation": false}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "TMPRSS2", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 4, "tested": 494, "frequency": 0.81, "cohort_count": 3, "frequency_range": {"min": 0.81, "max": 1.11}, "major_variants": ["E215K (n=1)", "S116* (n=1)", "K377Qfs*6 (n=1)", "N341del (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Curated target in the disease briefing.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 4/494 patients (0.81%).", "Without the 4 hypermutated patients: 4/490 (0.82%).", "Largest alteration is deep deletion: 58/489 (11.86%) in the reference cohort's copy-number profile.", "Observed in 3 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 4, "tested": 494, "frequency": 0.81, "frequency_excl_hypermutated": 0.82, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 9, "tested": 1013, "frequency": 0.89, "frequency_excl_hypermutated": 0.7, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": 25, "tested": 2257, "frequency": 1.11, "frequency_excl_hypermutated": 1.07, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 39.53, "width": 1.0, "reference": 39.53, "scale_max": 30.0}, "headline_alteration": {"kind": "deep deletion", "altered": 58, "tested": 489, "frequency": 11.86, "is_mutation": false}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "ERG", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 0, "tested": 494, "frequency": 0.0, "cohort_count": 2, "frequency_range": {"min": 0.0, "max": 0.71}, "major_variants": [], "evidence_confidence": "moderate", "disease_relevance": "Curated target in the disease briefing.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 0/494 patients (0.0%).", "Without the 4 hypermutated patients: 0/490 (0.0%).", "Largest alteration is deep deletion: 49/489 (10.02%) in the reference cohort's copy-number profile.", "Observed in 2 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 0, "tested": 494, "frequency": 0.0, "frequency_excl_hypermutated": 0.0, "counting_unit": "patients", "status": "not_observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 4, "tested": 1013, "frequency": 0.39, "frequency_excl_hypermutated": 0.3, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": 16, "tested": 2257, "frequency": 0.71, "frequency_excl_hypermutated": 0.67, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 33.4, "width": 1.0, "reference": 33.4, "scale_max": 30.0}, "headline_alteration": {"kind": "deep deletion", "altered": 49, "tested": 489, "frequency": 10.02, "is_mutation": false}, "altered_status": "not_observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "not_observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "SPOP", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 55, "tested": 494, "frequency": 11.13, "cohort_count": 3, "frequency_range": {"min": 9.08, "max": 14.09}, "major_variants": ["W131G (n=8)", "F133L (n=7)", "F133V (n=6)", "F133C (n=4)", "F102V (n=4)"], "evidence_confidence": "moderate", "disease_relevance": "Curated target in the disease briefing.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 55/494 patients (11.13%).", "Without the 4 hypermutated patients: 54/490 (11.02%).", "Observed in 3 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 55, "tested": 494, "frequency": 11.13, "frequency_excl_hypermutated": 11.02, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 92, "tested": 1013, "frequency": 9.08, "frequency_excl_hypermutated": 8.84, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": 318, "tested": 2257, "frequency": 14.09, "frequency_excl_hypermutated": 14.11, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 30.27, "width": 16.7, "reference": 37.1, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 55, "tested": 494, "frequency": 11.13, "is_mutation": true}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "KLK3", "alteration_types": ["SNV / small indel", "amplification"], "altered": 4, "tested": 494, "frequency": 0.81, "cohort_count": 2, "frequency_range": {"min": 0.59, "max": 0.81}, "major_variants": ["D102E (n=1)", "D182A (n=1)", "V42L (n=1)", "P129L (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Curated target in the disease briefing.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 4/494 patients (0.81%).", "Without the 4 hypermutated patients: 4/490 (0.82%).", "Observed in 2 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 4, "tested": 494, "frequency": 0.81, "frequency_excl_hypermutated": 0.82, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 6, "tested": 1013, "frequency": 0.59, "frequency_excl_hypermutated": 0.6, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": null, "tested": null, "frequency": null, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_assayed", "assayed": false, "assay_note": "Not on this cohort's gene panel.", "evaluable": false, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 1.97, "width": 1.0, "reference": 2.7, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 4, "tested": 494, "frequency": 0.81, "is_mutation": true}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "KMT2D", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 28, "tested": 494, "frequency": 5.67, "cohort_count": 3, "frequency_range": {"min": 5.67, "max": 6.65}, "major_variants": ["C5109F (n=1)", "E1167* (n=1)", "Q3394* (n=1)", "L2981V (n=1)", "E731Afs*17 (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 28/494 patients (5.67%).", "Without the 4 hypermutated patients: 26/490 (5.31%).", "Observed in 3 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 28, "tested": 494, "frequency": 5.67, "frequency_excl_hypermutated": 5.31, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 65, "tested": 1013, "frequency": 6.42, "frequency_excl_hypermutated": 5.53, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": 150, "tested": 2257, "frequency": 6.65, "frequency_excl_hypermutated": 6.48, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 18.9, "width": 3.27, "reference": 18.9, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 28, "tested": 494, "frequency": 5.67, "is_mutation": true}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "FOXA1", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 28, "tested": 494, "frequency": 5.67, "cohort_count": 3, "frequency_range": {"min": 5.67, "max": 15.55}, "major_variants": ["F254_N256delinsY (n=3)", "E255_N256del (n=1)", "A423Dfs*17 (n=1)", "*473Eext*34 (n=1)", "M253T (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 28/494 patients (5.67%).", "Without the 4 hypermutated patients: 27/490 (5.51%).", "Observed in 3 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 28, "tested": 494, "frequency": 5.67, "frequency_excl_hypermutated": 5.51, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 69, "tested": 1013, "frequency": 6.81, "frequency_excl_hypermutated": 6.63, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": 351, "tested": 2257, "frequency": 15.55, "frequency_excl_hypermutated": 15.53, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 18.9, "width": 32.93, "reference": 18.9, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 28, "tested": 494, "frequency": 5.67, "is_mutation": true}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "KMT2C", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 25, "tested": 494, "frequency": 5.06, "cohort_count": 3, "frequency_range": {"min": 5.06, "max": 6.82}, "major_variants": ["Y4440C (n=2)", "E3726Kfs*20 (n=1)", "P3034Lfs*4 (n=1)", "E3937Kfs*6 (n=1)", "Q1872* (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 25/494 patients (5.06%).", "Without the 4 hypermutated patients: 24/490 (4.9%).", "Observed in 3 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 25, "tested": 494, "frequency": 5.06, "frequency_excl_hypermutated": 4.9, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 65, "tested": 1013, "frequency": 6.42, "frequency_excl_hypermutated": 5.43, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": 154, "tested": 2257, "frequency": 6.82, "frequency_excl_hypermutated": 6.66, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 16.87, "width": 5.86, "reference": 16.87, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 25, "tested": 494, "frequency": 5.06, "is_mutation": true}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "CACNA1E", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 15, "tested": 494, "frequency": 3.04, "cohort_count": 2, "frequency_range": {"min": 3.04, "max": 3.65}, "major_variants": ["V1976M (n=1)", "R1396H (n=1)", "V2162I (n=1)", "V1231I (n=1)", "R946C (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 15/494 patients (3.04%).", "Without the 4 hypermutated patients: 14/490 (2.86%).", "Observed in 2 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 15, "tested": 494, "frequency": 3.04, "frequency_excl_hypermutated": 2.86, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 37, "tested": 1013, "frequency": 3.65, "frequency_excl_hypermutated": 3.22, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": null, "tested": null, "frequency": null, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_assayed", "assayed": false, "assay_note": "Not on this cohort's gene panel.", "evaluable": false, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 10.13, "width": 2.04, "reference": 10.13, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 15, "tested": 494, "frequency": 3.04, "is_mutation": true}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "MYO15A", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 14, "tested": 494, "frequency": 2.83, "cohort_count": 2, "frequency_range": {"min": 2.83, "max": 3.36}, "major_variants": ["R2262C (n=1)", "S1760Y (n=1)", "E313K (n=1)", "R950H (n=1)", "R192H (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 14/494 patients (2.83%).", "Without the 4 hypermutated patients: 12/490 (2.45%).", "Observed in 2 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 14, "tested": 494, "frequency": 2.83, "frequency_excl_hypermutated": 2.45, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 34, "tested": 1013, "frequency": 3.36, "frequency_excl_hypermutated": 2.71, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": null, "tested": null, "frequency": null, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_assayed", "assayed": false, "assay_note": "Not on this cohort's gene panel.", "evaluable": false, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 9.43, "width": 1.77, "reference": 9.43, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 14, "tested": 494, "frequency": 2.83, "is_mutation": true}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "ZFHX3", "alteration_types": ["SNV / small indel", "deep deletion"], "altered": 13, "tested": 494, "frequency": 2.63, "cohort_count": 3, "frequency_range": {"min": 2.63, "max": 6.64}, "major_variants": ["F1798Qfs*3 (n=1)", "R2998Q (n=1)", "L3355Afs*76 (n=1)", "G1901Rfs*14 (n=1)", "A776V (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 13/494 patients (2.63%).", "Without the 4 hypermutated patients: 10/490 (2.04%).", "Largest alteration is deep deletion: 29/489 (5.93%) in the reference cohort's copy-number profile.", "Observed in 3 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 13, "tested": 494, "frequency": 2.63, "frequency_excl_hypermutated": 2.04, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 41, "tested": 1013, "frequency": 4.05, "frequency_excl_hypermutated": 2.91, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": 141, "tested": 2122, "frequency": 6.64, "frequency_excl_hypermutated": 6.47, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 19.77, "width": 1.0, "reference": 19.77, "scale_max": 30.0}, "headline_alteration": {"kind": "deep deletion", "altered": 29, "tested": 489, "frequency": 5.93, "is_mutation": false}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "DCHS2", "alteration_types": ["SNV / small indel", "deep deletion", "amplification"], "altered": 12, "tested": 494, "frequency": 2.43, "cohort_count": 2, "frequency_range": {"min": 2.43, "max": 3.95}, "major_variants": ["F2421L (n=1)", "T1072I (n=1)", "R110Q (n=1)", "V526I (n=1)", "P1247T (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 12/494 patients (2.43%).", "Without the 4 hypermutated patients: 11/490 (2.24%).", "Observed in 2 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 12, "tested": 494, "frequency": 2.43, "frequency_excl_hypermutated": 2.24, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 40, "tested": 1013, "frequency": 3.95, "frequency_excl_hypermutated": 3.52, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": null, "tested": null, "frequency": null, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_assayed", "assayed": false, "assay_note": "Not on this cohort's gene panel.", "evaluable": false, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 8.1, "width": 5.07, "reference": 8.1, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 12, "tested": 494, "frequency": 2.43, "is_mutation": true}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "NALCN", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 11, "tested": 494, "frequency": 2.23, "cohort_count": 2, "frequency_range": {"min": 1.88, "max": 2.23}, "major_variants": ["R295C (n=1)", "A860T (n=1)", "A277T (n=1)", "E161Q (n=1)", "G1013S (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 11/494 patients (2.23%).", "Without the 4 hypermutated patients: 9/490 (1.84%).", "Observed in 2 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 11, "tested": 494, "frequency": 2.23, "frequency_excl_hypermutated": 1.84, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 19, "tested": 1013, "frequency": 1.88, "frequency_excl_hypermutated": 1.61, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": null, "tested": null, "frequency": null, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_assayed", "assayed": false, "assay_note": "Not on this cohort's gene panel.", "evaluable": false, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 6.27, "width": 1.16, "reference": 7.43, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 11, "tested": 494, "frequency": 2.23, "is_mutation": true}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "GRIA1", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 11, "tested": 494, "frequency": 2.23, "cohort_count": 2, "frequency_range": {"min": 1.88, "max": 2.23}, "major_variants": ["R455H (n=2)", "R855W (n=2)", "K775I (n=1)", "T657K (n=1)", "V618I (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 11/494 patients (2.23%).", "Without the 4 hypermutated patients: 10/490 (2.04%).", "Observed in 2 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 11, "tested": 494, "frequency": 2.23, "frequency_excl_hypermutated": 2.04, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 19, "tested": 1013, "frequency": 1.88, "frequency_excl_hypermutated": 1.71, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": null, "tested": null, "frequency": null, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_assayed", "assayed": false, "assay_note": "Not on this cohort's gene panel.", "evaluable": false, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 6.27, "width": 1.16, "reference": 7.43, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 11, "tested": 494, "frequency": 2.23, "is_mutation": true}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "FBN1", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 11, "tested": 494, "frequency": 2.23, "cohort_count": 2, "frequency_range": {"min": 1.97, "max": 2.23}, "major_variants": ["C2000F (n=1)", "Y798C (n=1)", "L771Tfs*7 (n=1)", "E1366K (n=1)", "P1225L (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 11/494 patients (2.23%).", "Without the 4 hypermutated patients: 9/490 (1.84%).", "Observed in 2 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 11, "tested": 494, "frequency": 2.23, "frequency_excl_hypermutated": 1.84, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 20, "tested": 1013, "frequency": 1.97, "frequency_excl_hypermutated": 1.61, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": null, "tested": null, "frequency": null, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_assayed", "assayed": false, "assay_note": "Not on this cohort's gene panel.", "evaluable": false, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 6.57, "width": 1.0, "reference": 7.43, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 11, "tested": 494, "frequency": 2.23, "is_mutation": true}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "CTNNB1", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 11, "tested": 494, "frequency": 2.23, "cohort_count": 3, "frequency_range": {"min": 2.23, "max": 3.94}, "major_variants": ["T41A (n=2)", "D32V (n=1)", "D32H (n=1)", "S37A (n=1)", "D32Y (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 11/494 patients (2.23%).", "Without the 4 hypermutated patients: 10/490 (2.04%).", "Observed in 3 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 11, "tested": 494, "frequency": 2.23, "frequency_excl_hypermutated": 2.04, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 30, "tested": 1013, "frequency": 2.96, "frequency_excl_hypermutated": 2.81, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": 89, "tested": 2257, "frequency": 3.94, "frequency_excl_hypermutated": 3.91, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 7.43, "width": 5.7, "reference": 7.43, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 11, "tested": 494, "frequency": 2.23, "is_mutation": true}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "ADGRB3", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 11, "tested": 494, "frequency": 2.23, "cohort_count": 2, "frequency_range": {"min": 2.23, "max": 2.37}, "major_variants": ["R588Q (n=1)", "W351L (n=1)", "D91N (n=1)", "S1176L (n=1)", "M1114L (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 11/494 patients (2.23%).", "Without the 4 hypermutated patients: 11/490 (2.24%).", "Largest alteration is deep deletion: 18/489 (3.68%) in the reference cohort's copy-number profile.", "Observed in 2 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 11, "tested": 494, "frequency": 2.23, "frequency_excl_hypermutated": 2.24, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 24, "tested": 1013, "frequency": 2.37, "frequency_excl_hypermutated": 2.21, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": null, "tested": null, "frequency": null, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_assayed", "assayed": false, "assay_note": "Not on this cohort's gene panel.", "evaluable": false, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 12.27, "width": 1.0, "reference": 12.27, "scale_max": 30.0}, "headline_alteration": {"kind": "deep deletion", "altered": 18, "tested": 489, "frequency": 3.68, "is_mutation": false}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "ZMYM3", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 10, "tested": 494, "frequency": 2.02, "cohort_count": 2, "frequency_range": {"min": 1.68, "max": 2.02}, "major_variants": ["X260_splice (n=1)", "Y1130* (n=1)", "P1296T (n=1)", "P1296R (n=1)", "N1154K (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 10/494 patients (2.02%).", "Without the 4 hypermutated patients: 8/490 (1.63%).", "Observed in 2 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 10, "tested": 494, "frequency": 2.02, "frequency_excl_hypermutated": 1.63, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 17, "tested": 1013, "frequency": 1.68, "frequency_excl_hypermutated": 1.51, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": null, "tested": null, "frequency": null, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_assayed", "assayed": false, "assay_note": "Not on this cohort's gene panel.", "evaluable": false, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 5.6, "width": 1.13, "reference": 6.73, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 10, "tested": 494, "frequency": 2.02, "is_mutation": true}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "SALL1", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 10, "tested": 494, "frequency": 2.02, "cohort_count": 2, "frequency_range": {"min": 1.58, "max": 2.02}, "major_variants": ["T745M (n=1)", "I343T (n=1)", "C717S (n=1)", "D814N (n=1)", "L1122P (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 10/494 patients (2.02%).", "Without the 4 hypermutated patients: 9/490 (1.84%).", "Largest alteration is deep deletion: 10/489 (2.04%) in the reference cohort's copy-number profile.", "Observed in 2 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 10, "tested": 494, "frequency": 2.02, "frequency_excl_hypermutated": 1.84, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 16, "tested": 1013, "frequency": 1.58, "frequency_excl_hypermutated": 1.21, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": null, "tested": null, "frequency": null, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_assayed", "assayed": false, "assay_note": "Not on this cohort's gene panel.", "evaluable": false, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 6.8, "width": 1.0, "reference": 6.8, "scale_max": 30.0}, "headline_alteration": {"kind": "deep deletion", "altered": 10, "tested": 489, "frequency": 2.04, "is_mutation": false}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "PIK3CA", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 10, "tested": 494, "frequency": 2.02, "cohort_count": 3, "frequency_range": {"min": 2.02, "max": 4.83}, "major_variants": ["E542K (n=2)", "H1047R (n=2)", "*1069* (n=1)", "R88Q (n=1)", "N345K (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 10/494 patients (2.02%).", "Without the 4 hypermutated patients: 9/490 (1.84%).", "Largest alteration is amplification: 11/489 (2.25%) in the reference cohort's copy-number profile.", "Observed in 3 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 10, "tested": 494, "frequency": 2.02, "frequency_excl_hypermutated": 1.84, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 29, "tested": 1013, "frequency": 2.86, "frequency_excl_hypermutated": 2.41, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": 109, "tested": 2257, "frequency": 4.83, "frequency_excl_hypermutated": 4.7, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 7.5, "width": 1.0, "reference": 7.5, "scale_max": 30.0}, "headline_alteration": {"kind": "amplification", "altered": 11, "tested": 489, "frequency": 2.25, "is_mutation": false}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "MXRA5", "alteration_types": ["SNV / small indel", "amplification"], "altered": 10, "tested": 494, "frequency": 2.02, "cohort_count": 2, "frequency_range": {"min": 1.88, "max": 2.02}, "major_variants": ["A254S (n=1)", "I2548Dfs*51 (n=1)", "T2106R (n=1)", "R1356H (n=1)", "R2297C (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 10/494 patients (2.02%).", "Without the 4 hypermutated patients: 9/490 (1.84%).", "Observed in 2 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 10, "tested": 494, "frequency": 2.02, "frequency_excl_hypermutated": 1.84, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 19, "tested": 1013, "frequency": 1.88, "frequency_excl_hypermutated": 1.71, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": null, "tested": null, "frequency": null, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_assayed", "assayed": false, "assay_note": "Not on this cohort's gene panel.", "evaluable": false, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 6.27, "width": 1.0, "reference": 6.73, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 10, "tested": 494, "frequency": 2.02, "is_mutation": true}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "FBN3", "alteration_types": ["SNV / small indel", "amplification"], "altered": 10, "tested": 494, "frequency": 2.02, "cohort_count": 2, "frequency_range": {"min": 2.02, "max": 2.07}, "major_variants": ["R1350C (n=1)", "C2526W (n=1)", "N1454K (n=1)", "R314C (n=1)", "C582S (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 10/494 patients (2.02%).", "Without the 4 hypermutated patients: 9/490 (1.84%).", "Observed in 2 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 10, "tested": 494, "frequency": 2.02, "frequency_excl_hypermutated": 1.84, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 21, "tested": 1013, "frequency": 2.07, "frequency_excl_hypermutated": 1.81, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": null, "tested": null, "frequency": null, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_assayed", "assayed": false, "assay_note": "Not on this cohort's gene panel.", "evaluable": false, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 6.73, "width": 1.0, "reference": 6.73, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 10, "tested": 494, "frequency": 2.02, "is_mutation": true}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "EPB41L3", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 10, "tested": 494, "frequency": 2.02, "cohort_count": 2, "frequency_range": {"min": 1.48, "max": 2.02}, "major_variants": ["I812T (n=1)", "K148T (n=1)", "T837M (n=1)", "R328Q (n=1)", "R694C (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 10/494 patients (2.02%).", "Without the 4 hypermutated patients: 9/490 (1.84%).", "Observed in 2 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 10, "tested": 494, "frequency": 2.02, "frequency_excl_hypermutated": 1.84, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 15, "tested": 1013, "frequency": 1.48, "frequency_excl_hypermutated": 1.31, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": null, "tested": null, "frequency": null, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_assayed", "assayed": false, "assay_note": "Not on this cohort's gene panel.", "evaluable": false, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 4.93, "width": 1.8, "reference": 6.73, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 10, "tested": 494, "frequency": 2.02, "is_mutation": true}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "CACNA1A", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 10, "tested": 494, "frequency": 2.02, "cohort_count": 2, "frequency_range": {"min": 1.88, "max": 2.02}, "major_variants": ["T808M (n=1)", "T542M (n=1)", "E532K (n=1)", "V86M (n=1)", "T1676N (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 10/494 patients (2.02%).", "Without the 4 hypermutated patients: 7/490 (1.43%).", "Observed in 2 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 10, "tested": 494, "frequency": 2.02, "frequency_excl_hypermutated": 1.43, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 19, "tested": 1013, "frequency": 1.88, "frequency_excl_hypermutated": 1.31, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": null, "tested": null, "frequency": null, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_assayed", "assayed": false, "assay_note": "Not on this cohort's gene panel.", "evaluable": false, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 6.27, "width": 1.0, "reference": 6.73, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 10, "tested": 494, "frequency": 2.02, "is_mutation": true}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "APC", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 10, "tested": 494, "frequency": 2.02, "cohort_count": 3, "frequency_range": {"min": 2.02, "max": 7.75}, "major_variants": ["S1539* (n=1)", "Q1123* (n=1)", "T1438Nfs*17 (n=1)", "R2714H (n=1)", "A1553V (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 10/494 patients (2.02%).", "Without the 4 hypermutated patients: 10/490 (2.04%).", "Largest alteration is deep deletion: 12/489 (2.45%) in the reference cohort's copy-number profile.", "Observed in 3 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 10, "tested": 494, "frequency": 2.02, "frequency_excl_hypermutated": 2.04, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 33, "tested": 1013, "frequency": 3.26, "frequency_excl_hypermutated": 2.91, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": 175, "tested": 2257, "frequency": 7.75, "frequency_excl_hypermutated": 7.63, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 8.17, "width": 1.0, "reference": 8.17, "scale_max": 30.0}, "headline_alteration": {"kind": "deep deletion", "altered": 12, "tested": 489, "frequency": 2.45, "is_mutation": false}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "STAB2", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 9, "tested": 494, "frequency": 1.82, "cohort_count": 2, "frequency_range": {"min": 1.82, "max": 2.17}, "major_variants": ["Y447C (n=1)", "H2138Y (n=1)", "R1940Q (n=1)", "E463K (n=1)", "A632T (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 9/494 patients (1.82%).", "Without the 4 hypermutated patients: 7/490 (1.43%).", "Observed in 2 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 9, "tested": 494, "frequency": 1.82, "frequency_excl_hypermutated": 1.43, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 22, "tested": 1013, "frequency": 2.17, "frequency_excl_hypermutated": 1.51, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": null, "tested": null, "frequency": null, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_assayed", "assayed": false, "assay_note": "Not on this cohort's gene panel.", "evaluable": false, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 6.07, "width": 1.16, "reference": 6.07, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 9, "tested": 494, "frequency": 1.82, "is_mutation": true}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "RNF213", "alteration_types": ["SNV / small indel", "amplification"], "altered": 9, "tested": 494, "frequency": 1.82, "cohort_count": 2, "frequency_range": {"min": 1.82, "max": 2.37}, "major_variants": ["L2860Rfs*12 (n=1)", "Y1967C (n=1)", "A2849V (n=1)", "M4673I (n=1)", "V3581I (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 9/494 patients (1.82%).", "Without the 4 hypermutated patients: 6/490 (1.22%).", "Observed in 2 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 9, "tested": 494, "frequency": 1.82, "frequency_excl_hypermutated": 1.22, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 24, "tested": 1013, "frequency": 2.37, "frequency_excl_hypermutated": 1.71, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": null, "tested": null, "frequency": null, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_assayed", "assayed": false, "assay_note": "Not on this cohort's gene panel.", "evaluable": false, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 6.07, "width": 1.83, "reference": 6.07, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 9, "tested": 494, "frequency": 1.82, "is_mutation": true}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "PCDH15", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 9, "tested": 494, "frequency": 1.82, "cohort_count": 2, "frequency_range": {"min": 1.82, "max": 2.76}, "major_variants": ["T1802K (n=1)", "P1420H (n=1)", "T301M (n=1)", "K1365N (n=1)", "P1631T (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 9/494 patients (1.82%).", "Without the 4 hypermutated patients: 8/490 (1.63%).", "Observed in 2 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 9, "tested": 494, "frequency": 1.82, "frequency_excl_hypermutated": 1.63, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 28, "tested": 1013, "frequency": 2.76, "frequency_excl_hypermutated": 2.41, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": null, "tested": null, "frequency": null, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_assayed", "assayed": false, "assay_note": "Not on this cohort's gene panel.", "evaluable": false, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 6.07, "width": 3.13, "reference": 6.07, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 9, "tested": 494, "frequency": 1.82, "is_mutation": true}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "NAV2", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 9, "tested": 494, "frequency": 1.82, "cohort_count": 2, "frequency_range": {"min": 1.82, "max": 2.37}, "major_variants": ["A468G (n=1)", "E2100G (n=1)", "A1790S (n=1)", "P29Q (n=1)", "K1638E (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 9/494 patients (1.82%).", "Without the 4 hypermutated patients: 8/490 (1.63%).", "Observed in 2 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 9, "tested": 494, "frequency": 1.82, "frequency_excl_hypermutated": 1.63, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 24, "tested": 1013, "frequency": 2.37, "frequency_excl_hypermutated": 2.11, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": null, "tested": null, "frequency": null, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_assayed", "assayed": false, "assay_note": "Not on this cohort's gene panel.", "evaluable": false, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 6.07, "width": 1.83, "reference": 6.07, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 9, "tested": 494, "frequency": 1.82, "is_mutation": true}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "MYH8", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 9, "tested": 494, "frequency": 1.82, "cohort_count": 2, "frequency_range": {"min": 1.48, "max": 1.82}, "major_variants": ["Q917H (n=1)", "V673A (n=1)", "A426V (n=1)", "G181R (n=1)", "Q1856R (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 9/494 patients (1.82%).", "Without the 4 hypermutated patients: 8/490 (1.63%).", "Observed in 2 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 9, "tested": 494, "frequency": 1.82, "frequency_excl_hypermutated": 1.63, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 15, "tested": 1013, "frequency": 1.48, "frequency_excl_hypermutated": 1.31, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": null, "tested": null, "frequency": null, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_assayed", "assayed": false, "assay_note": "Not on this cohort's gene panel.", "evaluable": false, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 4.93, "width": 1.14, "reference": 6.07, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 9, "tested": 494, "frequency": 1.82, "is_mutation": true}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "LAMA3", "alteration_types": ["SNV / small indel", "amplification"], "altered": 9, "tested": 494, "frequency": 1.82, "cohort_count": 2, "frequency_range": {"min": 1.82, "max": 1.97}, "major_variants": ["R2402* (n=1)", "X2681_splice (n=1)", "T2980I (n=1)", "E1508* (n=1)", "P1658Lfs*91 (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 9/494 patients (1.82%).", "Without the 4 hypermutated patients: 7/490 (1.43%).", "Observed in 2 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 9, "tested": 494, "frequency": 1.82, "frequency_excl_hypermutated": 1.43, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 20, "tested": 1013, "frequency": 1.97, "frequency_excl_hypermutated": 1.71, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": null, "tested": null, "frequency": null, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_assayed", "assayed": false, "assay_note": "Not on this cohort's gene panel.", "evaluable": false, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 6.07, "width": 1.0, "reference": 6.07, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 9, "tested": 494, "frequency": 1.82, "is_mutation": true}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "KDM6A", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 9, "tested": 494, "frequency": 1.82, "cohort_count": 3, "frequency_range": {"min": 1.82, "max": 3.59}, "major_variants": ["K987R (n=1)", "M1380Wfs*4 (n=1)", "X1392_splice (n=1)", "X1335_splice (n=1)", "N1117Y (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 9/494 patients (1.82%).", "Without the 4 hypermutated patients: 8/490 (1.63%).", "Observed in 3 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 9, "tested": 494, "frequency": 1.82, "frequency_excl_hypermutated": 1.63, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 29, "tested": 1013, "frequency": 2.86, "frequency_excl_hypermutated": 2.61, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": 81, "tested": 2257, "frequency": 3.59, "frequency_excl_hypermutated": 3.46, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 6.07, "width": 5.9, "reference": 6.07, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 9, "tested": 494, "frequency": 1.82, "is_mutation": true}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "HUWE1", "alteration_types": ["SNV / small indel", "amplification"], "altered": 9, "tested": 494, "frequency": 1.82, "cohort_count": 2, "frequency_range": {"min": 1.58, "max": 1.82}, "major_variants": ["R1894H (n=1)", "M1336V (n=1)", "R4007S (n=1)", "A3050V (n=1)", "R4122H (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 9/494 patients (1.82%).", "Without the 4 hypermutated patients: 8/490 (1.63%).", "Observed in 2 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 9, "tested": 494, "frequency": 1.82, "frequency_excl_hypermutated": 1.63, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 16, "tested": 1013, "frequency": 1.58, "frequency_excl_hypermutated": 1.21, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": null, "tested": null, "frequency": null, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_assayed", "assayed": false, "assay_note": "Not on this cohort's gene panel.", "evaluable": false, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 5.27, "width": 1.0, "reference": 6.07, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 9, "tested": 494, "frequency": 1.82, "is_mutation": true}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "GRM1", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 9, "tested": 494, "frequency": 1.82, "cohort_count": 2, "frequency_range": {"min": 1.58, "max": 1.82}, "major_variants": ["R297* (n=2)", "R379C (n=1)", "R275H (n=1)", "R981C (n=1)", "R684C (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 9/494 patients (1.82%).", "Without the 4 hypermutated patients: 8/490 (1.63%).", "Observed in 2 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 9, "tested": 494, "frequency": 1.82, "frequency_excl_hypermutated": 1.63, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 16, "tested": 1013, "frequency": 1.58, "frequency_excl_hypermutated": 1.41, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": null, "tested": null, "frequency": null, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_assayed", "assayed": false, "assay_note": "Not on this cohort's gene panel.", "evaluable": false, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 5.27, "width": 1.0, "reference": 6.07, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 9, "tested": 494, "frequency": 1.82, "is_mutation": true}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "GRIN2A", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 9, "tested": 494, "frequency": 1.82, "cohort_count": 3, "frequency_range": {"min": 1.82, "max": 3.28}, "major_variants": ["E1040D (n=1)", "E1123* (n=1)", "V109I (n=1)", "D973Y (n=1)", "F473I (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 9/494 patients (1.82%).", "Without the 4 hypermutated patients: 8/490 (1.63%).", "Observed in 3 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 9, "tested": 494, "frequency": 1.82, "frequency_excl_hypermutated": 1.63, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 27, "tested": 1013, "frequency": 2.67, "frequency_excl_hypermutated": 2.41, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": 74, "tested": 2257, "frequency": 3.28, "frequency_excl_hypermutated": 3.2, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 6.07, "width": 4.86, "reference": 6.07, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 9, "tested": 494, "frequency": 1.82, "is_mutation": true}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "GAD2", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 9, "tested": 494, "frequency": 1.82, "cohort_count": 2, "frequency_range": {"min": 1.38, "max": 1.82}, "major_variants": ["K222N (n=1)", "Y425* (n=1)", "G41R (n=1)", "G16D (n=1)", "N487Kfs*6 (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 9/494 patients (1.82%).", "Without the 4 hypermutated patients: 8/490 (1.63%).", "Observed in 2 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 9, "tested": 494, "frequency": 1.82, "frequency_excl_hypermutated": 1.63, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 14, "tested": 1013, "frequency": 1.38, "frequency_excl_hypermutated": 1.11, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": null, "tested": null, "frequency": null, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_assayed", "assayed": false, "assay_note": "Not on this cohort's gene panel.", "evaluable": false, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 4.6, "width": 1.47, "reference": 6.07, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 9, "tested": 494, "frequency": 1.82, "is_mutation": true}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "FCGBP", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 9, "tested": 494, "frequency": 1.82, "cohort_count": 2, "frequency_range": {"min": 1.82, "max": 2.37}, "major_variants": ["G976D (n=1)", "V531I (n=1)", "N4006S (n=1)", "R5341C (n=1)", "R134W (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 9/494 patients (1.82%).", "Without the 4 hypermutated patients: 8/490 (1.63%).", "Observed in 2 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 9, "tested": 494, "frequency": 1.82, "frequency_excl_hypermutated": 1.63, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 24, "tested": 1013, "frequency": 2.37, "frequency_excl_hypermutated": 2.01, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": null, "tested": null, "frequency": null, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_assayed", "assayed": false, "assay_note": "Not on this cohort's gene panel.", "evaluable": false, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 6.07, "width": 1.83, "reference": 6.07, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 9, "tested": 494, "frequency": 1.82, "is_mutation": true}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "FAT2", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 9, "tested": 494, "frequency": 1.82, "cohort_count": 2, "frequency_range": {"min": 1.82, "max": 2.76}, "major_variants": ["W4167Gfs*32 (n=1)", "H1551R (n=1)", "R308W (n=1)", "T3931M (n=1)", "G2251A (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 9/494 patients (1.82%).", "Without the 4 hypermutated patients: 8/490 (1.63%).", "Observed in 2 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 9, "tested": 494, "frequency": 1.82, "frequency_excl_hypermutated": 1.63, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 28, "tested": 1013, "frequency": 2.76, "frequency_excl_hypermutated": 2.51, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": null, "tested": null, "frequency": null, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_assayed", "assayed": false, "assay_note": "Not on this cohort's gene panel.", "evaluable": false, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 6.07, "width": 3.13, "reference": 6.07, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 9, "tested": 494, "frequency": 1.82, "is_mutation": true}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "COL6A3", "alteration_types": ["SNV / small indel", "deep deletion", "amplification"], "altered": 9, "tested": 494, "frequency": 1.82, "cohort_count": 2, "frequency_range": {"min": 1.82, "max": 1.97}, "major_variants": ["G1103E (n=1)", "V1885M (n=1)", "X2071_splice (n=1)", "P2232Q (n=1)", "S521L (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 9/494 patients (1.82%).", "Without the 4 hypermutated patients: 8/490 (1.63%).", "Observed in 2 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 9, "tested": 494, "frequency": 1.82, "frequency_excl_hypermutated": 1.63, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 20, "tested": 1013, "frequency": 1.97, "frequency_excl_hypermutated": 1.81, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": null, "tested": null, "frequency": null, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_assayed", "assayed": false, "assay_note": "Not on this cohort's gene panel.", "evaluable": false, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 6.07, "width": 1.0, "reference": 6.07, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 9, "tested": 494, "frequency": 1.82, "is_mutation": true}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "CDK12", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 9, "tested": 494, "frequency": 1.82, "cohort_count": 3, "frequency_range": {"min": 1.82, "max": 5.72}, "major_variants": ["G1461Afs*38 (n=1)", "G1446E (n=1)", "R858W (n=1)", "S343Efs*8 (n=1)", "Q598* (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 9/494 patients (1.82%).", "Without the 4 hypermutated patients: 8/490 (1.63%).", "Observed in 3 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 9, "tested": 494, "frequency": 1.82, "frequency_excl_hypermutated": 1.63, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 32, "tested": 1013, "frequency": 3.16, "frequency_excl_hypermutated": 3.02, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": 129, "tested": 2257, "frequency": 5.72, "frequency_excl_hypermutated": 5.59, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 6.07, "width": 13.0, "reference": 6.07, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 9, "tested": 494, "frequency": 1.82, "is_mutation": true}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}, {"gene": "ADGRL3", "alteration_types": ["SNV / small indel", "amplification", "deep deletion"], "altered": 9, "tested": 494, "frequency": 1.82, "cohort_count": 2, "frequency_range": {"min": 1.82, "max": 1.97}, "major_variants": ["R826H (n=2)", "R234W (n=1)", "W832L (n=1)", "I409N (n=1)", "R1139* (n=1)"], "evidence_confidence": "moderate", "disease_relevance": "Among the most frequently mutated genes in the reference cohort.", "targetability": "See the disease briefing's target table; not inferred from frequency.", "approved_drugs_other_diseases": [], "neuroblastoma_trials": [], "limitations": ["Non-silent calls in the study's sequenced sample list; patients, not samples.", "Cohort rows are not pooled; a zero is a measured absence in that profile, a dot is a gene the panel did not carry."], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "derived_insights": ["Reference cohort: Prostate Adenocarcinoma (TCGA, PanCancer Atlas), 9/494 patients (1.82%).", "Without the 4 hypermutated patients: 8/490 (1.63%).", "Observed in 2 of 3 cohorts; frequencies are cohort-specific and not pooled."], "cohort_frequencies": [{"cohort": "prad_tcga_pan_can_atlas_2018", "cohort_name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "altered": 9, "tested": 494, "frequency": 1.82, "frequency_excl_hypermutated": 1.63, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "494/494", "coverage_note": null, "source_id": "prad_tcga_pan_can_atlas_2018", "is_reference": true}, {"cohort": "prad_p1000", "cohort_name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "altered": 20, "tested": 1013, "frequency": 1.97, "frequency_excl_hypermutated": 1.71, "counting_unit": "patients", "status": "observed", "assayed": true, "assay_note": null, "evaluable": true, "coverage": "1013/1013", "coverage_note": null, "source_id": "prad_p1000", "is_reference": false}, {"cohort": "prostate_msk_2024", "cohort_name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "altered": null, "tested": null, "frequency": null, "frequency_excl_hypermutated": null, "counting_unit": "patients", "status": "not_assayed", "assayed": false, "assay_note": "Not on this cohort's gene panel.", "evaluable": false, "coverage": "2260/2260", "coverage_note": null, "source_id": "prostate_msk_2024", "is_reference": false}], "hgnc_id": null, "ensembl_id": null, "chromosome": null, "range_plot": {"left": 6.07, "width": 1.0, "reference": 6.07, "scale_max": 30.0}, "headline_alteration": {"kind": "SNV / small indel", "altered": 9, "tested": 494, "frequency": 1.82, "is_mutation": true}, "altered_status": "observed", "altered_unit": "patients", "tested_status": "observed", "tested_unit": "patients", "frequency_status": "observed", "frequency_unit": "percent", "cohort_count_status": "observed", "cohort_count_unit": "cohorts"}], "variants": [], "genomic_events": [{"event_type": "copy_number", "gene": "PTEN", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "deep deletion", "event_label": "PTEN deep deletion", "genomic_coordinate": null, "observed": 85, "observed_status": "observed", "observed_unit": "patients", "tested": 489, "tested_status": "observed", "tested_unit": "patients", "frequency": 17.38, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["prad_tcga_pan_can_atlas_2018"], "source_ids": ["prad_tcga_pan_can_atlas_2018_gistic"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "AR", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "amplification", "event_label": "AR amplification", "genomic_coordinate": null, "observed": 127, "observed_status": "observed", "observed_unit": "patients", "tested": 1013, "tested_status": "observed", "tested_unit": "patients", "frequency": 12.54, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["prad_p1000"], "source_ids": ["prad_p1000_cna"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "PTEN", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "deep deletion", "event_label": "PTEN deep deletion", "genomic_coordinate": null, "observed": 124, "observed_status": "observed", "observed_unit": "patients", "tested": 1013, "tested_status": "observed", "tested_unit": "patients", "frequency": 12.24, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["prad_p1000"], "source_ids": ["prad_p1000_cna"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "TMPRSS2", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "deep deletion", "event_label": "TMPRSS2 deep deletion", "genomic_coordinate": null, "observed": 58, "observed_status": "observed", "observed_unit": "patients", "tested": 489, "tested_status": "observed", "tested_unit": "patients", "frequency": 11.86, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["prad_tcga_pan_can_atlas_2018"], "source_ids": ["prad_tcga_pan_can_atlas_2018_gistic"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "PTEN", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "deep deletion", "event_label": "PTEN deep deletion", "genomic_coordinate": null, "observed": 262, "observed_status": "observed", "observed_unit": "patients", "tested": 2257, "tested_status": "observed", "tested_unit": "patients", "frequency": 11.61, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["prostate_msk_2024"], "source_ids": ["prostate_msk_2024_cna"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "AR", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "amplification", "event_label": "AR amplification", "genomic_coordinate": null, "observed": 236, "observed_status": "observed", "observed_unit": "patients", "tested": 2257, "tested_status": "observed", "tested_unit": "patients", "frequency": 10.46, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["prostate_msk_2024"], "source_ids": ["prostate_msk_2024_cna"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "ERG", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "deep deletion", "event_label": "ERG deep deletion", "genomic_coordinate": null, "observed": 49, "observed_status": "observed", "observed_unit": "patients", "tested": 489, "tested_status": "observed", "tested_unit": "patients", "frequency": 10.02, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["prad_tcga_pan_can_atlas_2018"], "source_ids": ["prad_tcga_pan_can_atlas_2018_gistic"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "RB1", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "deep deletion", "event_label": "RB1 deep deletion", "genomic_coordinate": null, "observed": 46, "observed_status": "observed", "observed_unit": "patients", "tested": 489, "tested_status": "observed", "tested_unit": "patients", "frequency": 9.41, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["prad_tcga_pan_can_atlas_2018"], "source_ids": ["prad_tcga_pan_can_atlas_2018_gistic"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "ZFHX3", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "deep deletion", "event_label": "ZFHX3 deep deletion", "genomic_coordinate": null, "observed": 29, "observed_status": "observed", "observed_unit": "patients", "tested": 489, "tested_status": "observed", "tested_unit": "patients", "frequency": 5.93, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["prad_tcga_pan_can_atlas_2018"], "source_ids": ["prad_tcga_pan_can_atlas_2018_gistic"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "TP53", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "deep deletion", "event_label": "TP53 deep deletion", "genomic_coordinate": null, "observed": 21, "observed_status": "observed", "observed_unit": "patients", "tested": 489, "tested_status": "observed", "tested_unit": "patients", "frequency": 4.29, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["prad_tcga_pan_can_atlas_2018"], "source_ids": ["prad_tcga_pan_can_atlas_2018_gistic"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "RB1", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "deep deletion", "event_label": "RB1 deep deletion", "genomic_coordinate": null, "observed": 41, "observed_status": "observed", "observed_unit": "patients", "tested": 1013, "tested_status": "observed", "tested_unit": "patients", "frequency": 4.05, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["prad_p1000"], "source_ids": ["prad_p1000_cna"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "PIK3CA", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "amplification", "event_label": "PIK3CA amplification", "genomic_coordinate": null, "observed": 41, "observed_status": "observed", "observed_unit": "patients", "tested": 1013, "tested_status": "observed", "tested_unit": "patients", "frequency": 4.05, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["prad_p1000"], "source_ids": ["prad_p1000_cna"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "ADGRB3", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "deep deletion", "event_label": "ADGRB3 deep deletion", "genomic_coordinate": null, "observed": 18, "observed_status": "observed", "observed_unit": "patients", "tested": 489, "tested_status": "observed", "tested_unit": "patients", "frequency": 3.68, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["prad_tcga_pan_can_atlas_2018"], "source_ids": ["prad_tcga_pan_can_atlas_2018_gistic"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "BRCA2", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "deep deletion", "event_label": "BRCA2 deep deletion", "genomic_coordinate": null, "observed": 17, "observed_status": "observed", "observed_unit": "patients", "tested": 489, "tested_status": "observed", "tested_unit": "patients", "frequency": 3.48, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["prad_tcga_pan_can_atlas_2018"], "source_ids": ["prad_tcga_pan_can_atlas_2018_gistic"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "RB1", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "deep deletion", "event_label": "RB1 deep deletion", "genomic_coordinate": null, "observed": 76, "observed_status": "observed", "observed_unit": "patients", "tested": 2257, "tested_status": "observed", "tested_unit": "patients", "frequency": 3.37, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["prostate_msk_2024"], "source_ids": ["prostate_msk_2024_cna"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "FOXA1", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "amplification", "event_label": "FOXA1 amplification", "genomic_coordinate": null, "observed": 32, "observed_status": "observed", "observed_unit": "patients", "tested": 1013, "tested_status": "observed", "tested_unit": "patients", "frequency": 3.16, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["prad_p1000"], "source_ids": ["prad_p1000_cna"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "FOXA1", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "amplification", "event_label": "FOXA1 amplification", "genomic_coordinate": null, "observed": 15, "observed_status": "observed", "observed_unit": "patients", "tested": 489, "tested_status": "observed", "tested_unit": "patients", "frequency": 3.07, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["prad_tcga_pan_can_atlas_2018"], "source_ids": ["prad_tcga_pan_can_atlas_2018_gistic"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "ADGRB3", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "deep deletion", "event_label": "ADGRB3 deep deletion", "genomic_coordinate": null, "observed": 30, "observed_status": "observed", "observed_unit": "patients", "tested": 1013, "tested_status": "observed", "tested_unit": "patients", "frequency": 2.96, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["prad_p1000"], "source_ids": ["prad_p1000_cna"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "BRCA2", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "deep deletion", "event_label": "BRCA2 deep deletion", "genomic_coordinate": null, "observed": 25, "observed_status": "observed", "observed_unit": "patients", "tested": 1013, "tested_status": "observed", "tested_unit": "patients", "frequency": 2.47, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["prad_p1000"], "source_ids": ["prad_p1000_cna"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "APC", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "deep deletion", "event_label": "APC deep deletion", "genomic_coordinate": null, "observed": 12, "observed_status": "observed", "observed_unit": "patients", "tested": 489, "tested_status": "observed", "tested_unit": "patients", "frequency": 2.45, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["prad_tcga_pan_can_atlas_2018"], "source_ids": ["prad_tcga_pan_can_atlas_2018_gistic"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "FOXA1", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "amplification", "event_label": "FOXA1 amplification", "genomic_coordinate": null, "observed": 54, "observed_status": "observed", "observed_unit": "patients", "tested": 2257, "tested_status": "observed", "tested_unit": "patients", "frequency": 2.39, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["prostate_msk_2024"], "source_ids": ["prostate_msk_2024_cna"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "ZFHX3", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "deep deletion", "event_label": "ZFHX3 deep deletion", "genomic_coordinate": null, "observed": 53, "observed_status": "observed", "observed_unit": "patients", "tested": 2257, "tested_status": "observed", "tested_unit": "patients", "frequency": 2.35, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["prostate_msk_2024"], "source_ids": ["prostate_msk_2024_cna"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "PIK3CA", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "amplification", "event_label": "PIK3CA amplification", "genomic_coordinate": null, "observed": 11, "observed_status": "observed", "observed_unit": "patients", "tested": 489, "tested_status": "observed", "tested_unit": "patients", "frequency": 2.25, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["prad_tcga_pan_can_atlas_2018"], "source_ids": ["prad_tcga_pan_can_atlas_2018_gistic"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "TP53", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "deep deletion", "event_label": "TP53 deep deletion", "genomic_coordinate": null, "observed": 50, "observed_status": "observed", "observed_unit": "patients", "tested": 2257, "tested_status": "observed", "tested_unit": "patients", "frequency": 2.22, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["prostate_msk_2024"], "source_ids": ["prostate_msk_2024_cna"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "FOLH1", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "deep deletion", "event_label": "FOLH1 deep deletion", "genomic_coordinate": null, "observed": 22, "observed_status": "observed", "observed_unit": "patients", "tested": 1013, "tested_status": "observed", "tested_unit": "patients", "frequency": 2.17, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["prad_p1000"], "source_ids": ["prad_p1000_cna"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "BRCA2", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "deep deletion", "event_label": "BRCA2 deep deletion", "genomic_coordinate": null, "observed": 49, "observed_status": "observed", "observed_unit": "patients", "tested": 2257, "tested_status": "observed", "tested_unit": "patients", "frequency": 2.17, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["prostate_msk_2024"], "source_ids": ["prostate_msk_2024_cna"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "ADGRL3", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "deep deletion", "event_label": "ADGRL3 deep deletion", "genomic_coordinate": null, "observed": 21, "observed_status": "observed", "observed_unit": "patients", "tested": 1013, "tested_status": "observed", "tested_unit": "patients", "frequency": 2.07, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["prad_p1000"], "source_ids": ["prad_p1000_cna"], "evidence_confidence": "moderate", "details": null}, {"event_type": "copy_number", "gene": "SALL1", "denominator_note": "Patients in the cohort's copy-number sample list.", "partner_gene": null, "alteration": "deep deletion", "event_label": "SALL1 deep deletion", "genomic_coordinate": null, "observed": 10, "observed_status": "observed", "observed_unit": "patients", "tested": 489, "tested_status": "observed", "tested_unit": "patients", "frequency": 2.04, "frequency_status": "observed", "frequency_unit": "percent", "cohorts": ["prad_tcga_pan_can_atlas_2018"], "source_ids": ["prad_tcga_pan_can_atlas_2018_gistic"], "evidence_confidence": "moderate", "details": null}], "modality_summary": [{"modality": "SNV / small indel", "available_cohorts": 3, "total_cohorts": 3}, {"modality": "Copy number (discrete)", "available_cohorts": 3, "total_cohorts": 3}, {"modality": "Structural variant (present, not read)", "available_cohorts": 3, "total_cohorts": 3}], "chromosome_summary": [], "cohorts": [{"name": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source": "cBioPortal", "accession": "prad_tcga_pan_can_atlas_2018", "patients": {"value": 494, "status": "observed", "unit": "patients"}, "samples": {"value": 494, "status": "observed", "unit": "samples"}, "disease_subtype": "Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "assay_type": "exome or genome", "sequencing_method": "WES (494)", "genome_build": "hg19", "alteration_types_available": ["SNV", "small indel", "amplification", "deep deletion", "structural variant (profile present, not read)"], "genes_assayed": "all coding genes", "primary_or_metastatic": null, "age_group": null, "retrieved_at": "2026-09-18", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "source_record_id": "prad_tcga_pan_can_atlas_2018", "is_demo": false, "assay_coverage": {"patients_with_calls": 494, "patients_in_roster": 494, "frequencies_computed": true, "samples_sequenced": 494, "samples_in_study": 494, "hypermutated_patients": 4, "median_mutations_per_sample": 26.0, "reason": null}}, {"name": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source": "cBioPortal", "accession": "prad_p1000", "patients": {"value": 1013, "status": "observed", "unit": "patients"}, "samples": {"value": 1013, "status": "observed", "unit": "samples"}, "disease_subtype": "Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "assay_type": "exome or genome", "sequencing_method": "WES (1013)", "genome_build": "hg19", "alteration_types_available": ["SNV", "small indel", "amplification", "deep deletion", "structural variant (profile present, not read)"], "genes_assayed": "all coding genes", "primary_or_metastatic": null, "age_group": null, "retrieved_at": "2026-09-18", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "source_record_id": "prad_p1000", "is_demo": false, "assay_coverage": {"patients_with_calls": 1013, "patients_in_roster": 1013, "frequencies_computed": true, "samples_sequenced": 1013, "samples_in_study": 1013, "hypermutated_patients": 18, "median_mutations_per_sample": 30, "reason": null}}, {"name": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "source": "cBioPortal", "accession": "prostate_msk_2024", "patients": {"value": 2257, "status": "observed", "unit": "patients"}, "samples": {"value": 2260, "status": "observed", "unit": "samples"}, "disease_subtype": "Prostate Cancer (MSK, Clin Cancer Res 2024)", "assay_type": "targeted panel", "sequencing_method": "IMPACT468 (1477), IMPACT410 (480), IMPACT505 (167), IMPACT341 (136)", "genome_build": "hg19", "alteration_types_available": ["SNV", "small indel", "amplification", "deep deletion", "structural variant (profile present, not read)"], "genes_assayed": "panel genes only; per-gene denominators", "primary_or_metastatic": null, "age_group": null, "retrieved_at": "2026-09-18", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "source_record_id": "prostate_msk_2024", "is_demo": false, "assay_coverage": {"patients_with_calls": 2257, "patients_in_roster": 2257, "frequencies_computed": true, "samples_sequenced": 2260, "samples_in_study": 2260, "hypermutated_patients": 4, "median_mutations_per_sample": 3.0, "reason": null}}], "sources": [{"source_name": "cBioPortal · Prostate Adenocarcinoma (TCGA, PanCancer Atlas)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018", "source_record_id": "prad_tcga_pan_can_atlas_2018", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)", "source_url": "https://www.cbioportal.org/study/summary?id=prad_p1000", "source_record_id": "prad_p1000", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}, {"source_name": "cBioPortal · Prostate Cancer (MSK, Clin Cancer Res 2024)", "source_url": "https://www.cbioportal.org/study/summary?id=prostate_msk_2024", "source_record_id": "prostate_msk_2024", "source_version": null, "retrieved_at": "2026-09-18", "processing_version": null, "normalization_method": "patient-level, non-silent calls, panel-aware denominator", "genome_build": "hg19", "licence": "cBioPortal public data; the study's own data-use terms apply (TCGA: open; TARGET: OCG terms; others as published).", "is_demo": false}], "limitations": ["A cBioPortal public-API snapshot retrieved 2026-09-18; the page does not refresh source data at request time.", "Counts are patients with at least one non-silent call in the study's sequenced sample list; silent, intronic and UTR calls are excluded.", "For targeted-panel cohorts each gene divides by the patients whose panel carried it; a gene absent from the panel is shown as not assayed, not as zero.", "Copy-number rows use discrete calls (2 = high-level amplification, −2 = deep deletion) against the cohort's copy-number sample list, which is a different roster from the sequenced one.", "Cohorts are not pooled. Cross-study patient overlap has not been checked and no disease-wide frequency is reported.", "Structural variants and fusions are not read in this snapshot even where the study carries a profile; germline variants, mutational signatures, TMB and MSI are not reported.", "The gene set is the briefing's curated targets plus the reference cohort's most frequently mutated genes; it is not genome-wide."], "answer_block": ["In Prostate Adenocarcinoma (TCGA, PanCancer Atlas) (494 sequenced patients, exome or genome), the most frequently altered of the 48 genes shown are PTEN 17.38% (deep deletion), TMPRSS2 11.86% (deep deletion), TP53 11.54%, SPOP 11.13%, ERG 10.02% (deep deletion). Each figure divides by the patients on whom that gene could be called.", "4 of 494 patients are hypermutated (more than 260 non-silent mutations, ten times the cohort median of 26); every gene's frequency without them is beside the headline.", "Of the briefing's 12 curated targets, 4 are altered in under 2% of this cohort (AR, FOLH1, CYP17A1, KLK3): targets by expression, dependency or drug label, not by mutation. Frequency is not targetability, in either direction.", "3 cohorts are shown and none are pooled; overlap between them has not been checked and there is no disease-wide percentage."], "key_findings": [{"finding": "PTEN is deleted in 85 of 489 patients in Prostate Adenocarcinoma (TCGA, PanCancer Atlas).", "numerator": 85, "denominator": 489, "frequency": 17.38, "cohorts": 3, "evidence_confidence": "moderate", "source": "prad_tcga_pan_can_atlas_2018", "retrieved_at": "2026-09-18"}, {"finding": "TMPRSS2 is deleted in 58 of 489 patients in Prostate Adenocarcinoma (TCGA, PanCancer Atlas).", "numerator": 58, "denominator": 489, "frequency": 11.86, "cohorts": 3, "evidence_confidence": "moderate", "source": "prad_tcga_pan_can_atlas_2018", "retrieved_at": "2026-09-18"}, {"finding": "TP53 is mutated in 57 of 494 patients in Prostate Adenocarcinoma (TCGA, PanCancer Atlas).", "numerator": 57, "denominator": 494, "frequency": 11.54, "cohorts": 3, "evidence_confidence": "moderate", "source": "prad_tcga_pan_can_atlas_2018", "retrieved_at": "2026-09-18"}], "research_gaps": [{"kind": "Structural variants", "text": "Read the structural-variant profiles the studies carry; fusions are the defining event in several of these diseases."}, {"kind": "Context", "text": "Stage, subtype, age and treatment line are not attached to any count; the cohorts differ on all four."}, {"kind": "Interpretation", "text": "Activating versus inactivating, actionable versus not, and evidence level are not inferred here; the briefing's target table carries the drug and trial facts."}], "observations": [], "data_status": "PUBLIC SOURCE SNAPSHOT", "is_demo": false, "reference_cohort": "prad_tcga_pan_can_atlas_2018", "region_events": [], "matrix": [{"label": "AR", "kind": "SNV / small indel", "gene": "AR", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 0.4, "altered": 2, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 4.74, "altered": 48, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "observed", "frequency": 4.12, "altered": 93, "tested": 2257, "note": null}]}, {"label": "AR", "kind": "amplification", "gene": "AR", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 1.02, "altered": 5, "tested": 489, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}, {"cohort": "prad_p1000", "status": "observed", "frequency": 12.54, "altered": 127, "tested": 1013, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}, {"cohort": "prostate_msk_2024", "status": "observed", "frequency": 10.46, "altered": 236, "tested": 2257, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}]}, {"label": "FOLH1", "kind": "SNV / small indel", "gene": "FOLH1", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "not_observed", "frequency": 0.0, "altered": 0, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 0.1, "altered": 1, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "not_assayed", "frequency": null, "altered": null, "tested": null, "note": "Not on this cohort's gene panel."}]}, {"label": "FOLH1", "kind": "deep deletion", "gene": "FOLH1", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 0.41, "altered": 2, "tested": 489, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}, {"cohort": "prad_p1000", "status": "observed", "frequency": 2.17, "altered": 22, "tested": 1013, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}, {"cohort": "prostate_msk_2024", "status": "not_observed", "frequency": 0.0, "altered": 0, "tested": 2257, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}]}, {"label": "CYP17A1", "kind": "SNV / small indel", "gene": "CYP17A1", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 0.2, "altered": 1, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 0.2, "altered": 2, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "not_assayed", "frequency": null, "altered": null, "tested": null, "note": "Not on this cohort's gene panel."}]}, {"label": "BRCA2", "kind": "SNV / small indel", "gene": "BRCA2", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 1.62, "altered": 8, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 2.86, "altered": 29, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "observed", "frequency": 3.99, "altered": 90, "tested": 2257, "note": null}]}, {"label": "BRCA2", "kind": "deep deletion", "gene": "BRCA2", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 3.48, "altered": 17, "tested": 489, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}, {"cohort": "prad_p1000", "status": "observed", "frequency": 2.47, "altered": 25, "tested": 1013, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}, {"cohort": "prostate_msk_2024", "status": "observed", "frequency": 2.17, "altered": 49, "tested": 2257, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}]}, {"label": "ATM", "kind": "SNV / small indel", "gene": "ATM", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 4.05, "altered": 20, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 3.75, "altered": 38, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "observed", "frequency": 4.25, "altered": 96, "tested": 2257, "note": null}]}, {"label": "PTEN", "kind": "SNV / small indel", "gene": "PTEN", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 3.64, "altered": 18, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 4.24, "altered": 43, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "observed", "frequency": 7.98, "altered": 180, "tested": 2257, "note": null}]}, {"label": "PTEN", "kind": "deep deletion", "gene": "PTEN", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 17.38, "altered": 85, "tested": 489, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}, {"cohort": "prad_p1000", "status": "observed", "frequency": 12.24, "altered": 124, "tested": 1013, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}, {"cohort": "prostate_msk_2024", "status": "observed", "frequency": 11.61, "altered": 262, "tested": 2257, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}]}, {"label": "TP53", "kind": "SNV / small indel", "gene": "TP53", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 11.54, "altered": 57, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 18.56, "altered": 188, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "observed", "frequency": 28.71, "altered": 648, "tested": 2257, "note": null}]}, {"label": "TP53", "kind": "deep deletion", "gene": "TP53", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 4.29, "altered": 21, "tested": 489, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}, {"cohort": "prad_p1000", "status": "observed", "frequency": 1.97, "altered": 20, "tested": 1013, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}, {"cohort": "prostate_msk_2024", "status": "observed", "frequency": 2.22, "altered": 50, "tested": 2257, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}]}, {"label": "RB1", "kind": "SNV / small indel", "gene": "RB1", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 0.61, "altered": 3, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 1.48, "altered": 15, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "observed", "frequency": 3.23, "altered": 73, "tested": 2257, "note": null}]}, {"label": "RB1", "kind": "deep deletion", "gene": "RB1", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 9.41, "altered": 46, "tested": 489, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}, {"cohort": "prad_p1000", "status": "observed", "frequency": 4.05, "altered": 41, "tested": 1013, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}, {"cohort": "prostate_msk_2024", "status": "observed", "frequency": 3.37, "altered": 76, "tested": 2257, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}]}, {"label": "TMPRSS2", "kind": "SNV / small indel", "gene": "TMPRSS2", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 0.81, "altered": 4, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 0.89, "altered": 9, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "observed", "frequency": 1.11, "altered": 25, "tested": 2257, "note": null}]}, {"label": "TMPRSS2", "kind": "deep deletion", "gene": "TMPRSS2", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 11.86, "altered": 58, "tested": 489, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}, {"cohort": "prad_p1000", "status": "not_observed", "frequency": 0.0, "altered": 0, "tested": 1013, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}, {"cohort": "prostate_msk_2024", "status": "observed", "frequency": 1.06, "altered": 24, "tested": 2257, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}]}, {"label": "ERG", "kind": "SNV / small indel", "gene": "ERG", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "not_observed", "frequency": 0.0, "altered": 0, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 0.39, "altered": 4, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "observed", "frequency": 0.71, "altered": 16, "tested": 2257, "note": null}]}, {"label": "ERG", "kind": "deep deletion", "gene": "ERG", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 10.02, "altered": 49, "tested": 489, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}, {"cohort": "prad_p1000", "status": "not_observed", "frequency": 0.0, "altered": 0, "tested": 1013, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}, {"cohort": "prostate_msk_2024", "status": "not_observed", "frequency": 0.0, "altered": 0, "tested": 2257, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}]}, {"label": "SPOP", "kind": "SNV / small indel", "gene": "SPOP", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 11.13, "altered": 55, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 9.08, "altered": 92, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "observed", "frequency": 14.09, "altered": 318, "tested": 2257, "note": null}]}, {"label": "KLK3", "kind": "SNV / small indel", "gene": "KLK3", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 0.81, "altered": 4, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 0.59, "altered": 6, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "not_assayed", "frequency": null, "altered": null, "tested": null, "note": "Not on this cohort's gene panel."}]}, {"label": "KMT2D", "kind": "SNV / small indel", "gene": "KMT2D", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 5.67, "altered": 28, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 6.42, "altered": 65, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "observed", "frequency": 6.65, "altered": 150, "tested": 2257, "note": null}]}, {"label": "FOXA1", "kind": "SNV / small indel", "gene": "FOXA1", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 5.67, "altered": 28, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 6.81, "altered": 69, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "observed", "frequency": 15.55, "altered": 351, "tested": 2257, "note": null}]}, {"label": "FOXA1", "kind": "amplification", "gene": "FOXA1", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 3.07, "altered": 15, "tested": 489, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}, {"cohort": "prad_p1000", "status": "observed", "frequency": 3.16, "altered": 32, "tested": 1013, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}, {"cohort": "prostate_msk_2024", "status": "observed", "frequency": 2.39, "altered": 54, "tested": 2257, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}]}, {"label": "KMT2C", "kind": "SNV / small indel", "gene": "KMT2C", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 5.06, "altered": 25, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 6.42, "altered": 65, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "observed", "frequency": 6.82, "altered": 154, "tested": 2257, "note": null}]}, {"label": "CACNA1E", "kind": "SNV / small indel", "gene": "CACNA1E", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 3.04, "altered": 15, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 3.65, "altered": 37, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "not_assayed", "frequency": null, "altered": null, "tested": null, "note": "Not on this cohort's gene panel."}]}, {"label": "MYO15A", "kind": "SNV / small indel", "gene": "MYO15A", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 2.83, "altered": 14, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 3.36, "altered": 34, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "not_assayed", "frequency": null, "altered": null, "tested": null, "note": "Not on this cohort's gene panel."}]}, {"label": "ZFHX3", "kind": "SNV / small indel", "gene": "ZFHX3", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 2.63, "altered": 13, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 4.05, "altered": 41, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "observed", "frequency": 6.64, "altered": 141, "tested": 2122, "note": null}]}, {"label": "ZFHX3", "kind": "deep deletion", "gene": "ZFHX3", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 5.93, "altered": 29, "tested": 489, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}, {"cohort": "prad_p1000", "status": "not_observed", "frequency": 0.0, "altered": 0, "tested": 1013, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}, {"cohort": "prostate_msk_2024", "status": "observed", "frequency": 2.35, "altered": 53, "tested": 2257, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}]}, {"label": "DCHS2", "kind": "SNV / small indel", "gene": "DCHS2", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 2.43, "altered": 12, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 3.95, "altered": 40, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "not_assayed", "frequency": null, "altered": null, "tested": null, "note": "Not on this cohort's gene panel."}]}, {"label": "NALCN", "kind": "SNV / small indel", "gene": "NALCN", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 2.23, "altered": 11, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 1.88, "altered": 19, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "not_assayed", "frequency": null, "altered": null, "tested": null, "note": "Not on this cohort's gene panel."}]}, {"label": "GRIA1", "kind": "SNV / small indel", "gene": "GRIA1", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 2.23, "altered": 11, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 1.88, "altered": 19, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "not_assayed", "frequency": null, "altered": null, "tested": null, "note": "Not on this cohort's gene panel."}]}, {"label": "FBN1", "kind": "SNV / small indel", "gene": "FBN1", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 2.23, "altered": 11, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 1.97, "altered": 20, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "not_assayed", "frequency": null, "altered": null, "tested": null, "note": "Not on this cohort's gene panel."}]}, {"label": "CTNNB1", "kind": "SNV / small indel", "gene": "CTNNB1", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 2.23, "altered": 11, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 2.96, "altered": 30, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "observed", "frequency": 3.94, "altered": 89, "tested": 2257, "note": null}]}, {"label": "ADGRB3", "kind": "SNV / small indel", "gene": "ADGRB3", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 2.23, "altered": 11, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 2.37, "altered": 24, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "not_assayed", "frequency": null, "altered": null, "tested": null, "note": "Not on this cohort's gene panel."}]}, {"label": "ADGRB3", "kind": "deep deletion", "gene": "ADGRB3", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 3.68, "altered": 18, "tested": 489, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}, {"cohort": "prad_p1000", "status": "observed", "frequency": 2.96, "altered": 30, "tested": 1013, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}, {"cohort": "prostate_msk_2024", "status": "not_observed", "frequency": 0.0, "altered": 0, "tested": 2257, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}]}, {"label": "ZMYM3", "kind": "SNV / small indel", "gene": "ZMYM3", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 2.02, "altered": 10, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 1.68, "altered": 17, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "not_assayed", "frequency": null, "altered": null, "tested": null, "note": "Not on this cohort's gene panel."}]}, {"label": "SALL1", "kind": "SNV / small indel", "gene": "SALL1", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 2.02, "altered": 10, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 1.58, "altered": 16, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "not_assayed", "frequency": null, "altered": null, "tested": null, "note": "Not on this cohort's gene panel."}]}, {"label": "SALL1", "kind": "deep deletion", "gene": "SALL1", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 2.04, "altered": 10, "tested": 489, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}, {"cohort": "prad_p1000", "status": "not_observed", "frequency": 0.0, "altered": 0, "tested": 1013, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}, {"cohort": "prostate_msk_2024", "status": "not_observed", "frequency": 0.0, "altered": 0, "tested": 2257, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}]}, {"label": "PIK3CA", "kind": "SNV / small indel", "gene": "PIK3CA", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 2.02, "altered": 10, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 2.86, "altered": 29, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "observed", "frequency": 4.83, "altered": 109, "tested": 2257, "note": null}]}, {"label": "PIK3CA", "kind": "amplification", "gene": "PIK3CA", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 2.25, "altered": 11, "tested": 489, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}, {"cohort": "prad_p1000", "status": "observed", "frequency": 4.05, "altered": 41, "tested": 1013, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}, {"cohort": "prostate_msk_2024", "status": "observed", "frequency": 0.18, "altered": 4, "tested": 2257, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}]}, {"label": "MXRA5", "kind": "SNV / small indel", "gene": "MXRA5", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 2.02, "altered": 10, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 1.88, "altered": 19, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "not_assayed", "frequency": null, "altered": null, "tested": null, "note": "Not on this cohort's gene panel."}]}, {"label": "FBN3", "kind": "SNV / small indel", "gene": "FBN3", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 2.02, "altered": 10, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 2.07, "altered": 21, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "not_assayed", "frequency": null, "altered": null, "tested": null, "note": "Not on this cohort's gene panel."}]}, {"label": "EPB41L3", "kind": "SNV / small indel", "gene": "EPB41L3", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 2.02, "altered": 10, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 1.48, "altered": 15, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "not_assayed", "frequency": null, "altered": null, "tested": null, "note": "Not on this cohort's gene panel."}]}, {"label": "CACNA1A", "kind": "SNV / small indel", "gene": "CACNA1A", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 2.02, "altered": 10, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 1.88, "altered": 19, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "not_assayed", "frequency": null, "altered": null, "tested": null, "note": "Not on this cohort's gene panel."}]}, {"label": "APC", "kind": "SNV / small indel", "gene": "APC", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 2.02, "altered": 10, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 3.26, "altered": 33, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "observed", "frequency": 7.75, "altered": 175, "tested": 2257, "note": null}]}, {"label": "APC", "kind": "deep deletion", "gene": "APC", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 2.45, "altered": 12, "tested": 489, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}, {"cohort": "prad_p1000", "status": "observed", "frequency": 1.78, "altered": 18, "tested": 1013, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}, {"cohort": "prostate_msk_2024", "status": "observed", "frequency": 1.37, "altered": 31, "tested": 2257, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}]}, {"label": "STAB2", "kind": "SNV / small indel", "gene": "STAB2", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 1.82, "altered": 9, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 2.17, "altered": 22, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "not_assayed", "frequency": null, "altered": null, "tested": null, "note": "Not on this cohort's gene panel."}]}, {"label": "RNF213", "kind": "SNV / small indel", "gene": "RNF213", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 1.82, "altered": 9, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 2.37, "altered": 24, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "not_assayed", "frequency": null, "altered": null, "tested": null, "note": "Not on this cohort's gene panel."}]}, {"label": "PCDH15", "kind": "SNV / small indel", "gene": "PCDH15", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 1.82, "altered": 9, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 2.76, "altered": 28, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "not_assayed", "frequency": null, "altered": null, "tested": null, "note": "Not on this cohort's gene panel."}]}, {"label": "NAV2", "kind": "SNV / small indel", "gene": "NAV2", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 1.82, "altered": 9, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 2.37, "altered": 24, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "not_assayed", "frequency": null, "altered": null, "tested": null, "note": "Not on this cohort's gene panel."}]}, {"label": "MYH8", "kind": "SNV / small indel", "gene": "MYH8", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 1.82, "altered": 9, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 1.48, "altered": 15, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "not_assayed", "frequency": null, "altered": null, "tested": null, "note": "Not on this cohort's gene panel."}]}, {"label": "LAMA3", "kind": "SNV / small indel", "gene": "LAMA3", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 1.82, "altered": 9, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 1.97, "altered": 20, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "not_assayed", "frequency": null, "altered": null, "tested": null, "note": "Not on this cohort's gene panel."}]}, {"label": "KDM6A", "kind": "SNV / small indel", "gene": "KDM6A", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 1.82, "altered": 9, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 2.86, "altered": 29, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "observed", "frequency": 3.59, "altered": 81, "tested": 2257, "note": null}]}, {"label": "HUWE1", "kind": "SNV / small indel", "gene": "HUWE1", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 1.82, "altered": 9, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 1.58, "altered": 16, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "not_assayed", "frequency": null, "altered": null, "tested": null, "note": "Not on this cohort's gene panel."}]}, {"label": "GRM1", "kind": "SNV / small indel", "gene": "GRM1", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 1.82, "altered": 9, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 1.58, "altered": 16, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "not_assayed", "frequency": null, "altered": null, "tested": null, "note": "Not on this cohort's gene panel."}]}, {"label": "GRIN2A", "kind": "SNV / small indel", "gene": "GRIN2A", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 1.82, "altered": 9, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 2.67, "altered": 27, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "observed", "frequency": 3.28, "altered": 74, "tested": 2257, "note": null}]}, {"label": "GAD2", "kind": "SNV / small indel", "gene": "GAD2", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 1.82, "altered": 9, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 1.38, "altered": 14, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "not_assayed", "frequency": null, "altered": null, "tested": null, "note": "Not on this cohort's gene panel."}]}, {"label": "FCGBP", "kind": "SNV / small indel", "gene": "FCGBP", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 1.82, "altered": 9, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 2.37, "altered": 24, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "not_assayed", "frequency": null, "altered": null, "tested": null, "note": "Not on this cohort's gene panel."}]}, {"label": "FAT2", "kind": "SNV / small indel", "gene": "FAT2", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 1.82, "altered": 9, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 2.76, "altered": 28, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "not_assayed", "frequency": null, "altered": null, "tested": null, "note": "Not on this cohort's gene panel."}]}, {"label": "COL6A3", "kind": "SNV / small indel", "gene": "COL6A3", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 1.82, "altered": 9, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 1.97, "altered": 20, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "not_assayed", "frequency": null, "altered": null, "tested": null, "note": "Not on this cohort's gene panel."}]}, {"label": "CDK12", "kind": "SNV / small indel", "gene": "CDK12", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 1.82, "altered": 9, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 3.16, "altered": 32, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "observed", "frequency": 5.72, "altered": 129, "tested": 2257, "note": null}]}, {"label": "ADGRL3", "kind": "SNV / small indel", "gene": "ADGRL3", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 1.82, "altered": 9, "tested": 494, "note": null}, {"cohort": "prad_p1000", "status": "observed", "frequency": 1.97, "altered": 20, "tested": 1013, "note": null}, {"cohort": "prostate_msk_2024", "status": "not_assayed", "frequency": null, "altered": null, "tested": null, "note": "Not on this cohort's gene panel."}]}, {"label": "ADGRL3", "kind": "deep deletion", "gene": "ADGRL3", "cells": [{"cohort": "prad_tcga_pan_can_atlas_2018", "status": "observed", "frequency": 0.41, "altered": 2, "tested": 489, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}, {"cohort": "prad_p1000", "status": "observed", "frequency": 2.07, "altered": 21, "tested": 1013, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}, {"cohort": "prostate_msk_2024", "status": "not_observed", "frequency": 0.0, "altered": 0, "tested": 2257, "note": "Discrete copy-number call; divides by the cohort's copy-number roster."}]}]}